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Letters to the Editorfollow surgical oncologic principles
and should be regarded as a bailout
procedure and used judiciously.
Raja M. Flores, MD
Division of Thoracic Surgery
Mount Sinai School of Medicine
New York, NYReference
1. Flores RM, Ihekweazu U, Dycocco J, Rizk NP,
Rusch VW, Bains MS, et al. Video-assisted thora-
coscopic surgery (VATS) lobectomy: catastrophic
intraoperative complication. J Thorac Cardiavasc
Surg. 2011;142:1412-7.
doi:10.1016/j.jtcvs.2012.03.045WILLTHE REAL CULPRIT OF
HETEROGRAFT VALVE
CALCIFICATION PLEASE
STAND UP?
To the Editor:
Sinha and colleagues1 are not the
first to implicate glutaraldehyde as
a culprit for tissue valve calcification.
Although they are to be commended
for their careful methods and the sug-
gestion that glutaraldehyde concentra-
tion and exposure times appear to
correlate with the degree of calcifica-
tion, they unfortunately failed to reach
far enough back into the literature to
recognize that most of their questions
had already been answered by others.2
A closer look at the literature might
also have led these researchers to ar-
rive at a different conclusion; that is,
calcific degeneration of heterograft
tissues is primarily an immunologic
phenomenon.
Alain Carpentier and his wife So-
phie, a biochemist, are given credit
for the introduction of aldehyde chem-
istry to themodernmanufacture of het-
erograft tissue valves.3 At the time,
they did not advance an argument
that aldehyde preservation rendered
heterograft tissues nonimmunogenic.
That perception belongs to perspica-
cious marketing departments within
the tissue valve industry. The observa-
tion that calcific degeneration of het-
erograft valves is an age-relatedThe Journalphenomenon was an early and impor-
tant clue to the problem of tissue valve
durability.4 These issues notwithstand-
ing, the Carpentiers’ discovery had al-
ready spawned the multibillion dollar
industry of heterograft tissue heart
valves.
More than30years ago, Salgaller and
Bajpai5 detected both cellular and
humoral immune responses to
glutaraldehyde-treated and untreated
bovine pericardium. Their data pro-
vided the first real proof that
glutaraldehyde-preserved heterograft
tissues are not biologically inert and re-
main antigenic. The association be-
tween a smoldering immune response
and tissue valve durability was never
widely recognized,however, andglutar-
aldehyde continued to be the presumed
cause of heterograft calcification, lead-
ing researchers and companies to search
for new tissue treatments designed to re-
tard calcification.
Love and associates6 first described
the successful use of autologous peri-
cardium briefly treated in 0.6%
glutaraldehyde for use as a stent-
mounted valve replacement. Since
this introduction, multiple investiga-
tors have reported wide success with
the use of autologous pericardium
briefly treated in 0.6% glutaraldehyde
for the replacement of semilunar heart
valves7 and the repair of damaged and
shortened mitral valve leaflets.8 All
these techniques have proved durable,
and in none of the published experi-
ences, including those with pediatric
or very young patients, has calcific
degeneration been considered
a limitation.
The more than 20-year clinical ex-
perience with autologous pericardium
briefly immersed in glutaraldehyde
and used for valve reconstruction
should finally dispel any perception
that aldehydes are directly responsible
for calcific degeneration of tissue
valves.
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We thank Mr Love for responding
to our article1 and for emphasizing
the importance of immune mecha-
nisms in heterograft calcification. We
are in agreement that aldehyde treat-
ment is just one of several factors
that can exacerbate calcification of
implanted tissues. In the clinical set-
ting of pediatric cardiac surgery,
where autologous pericardium is often
used and immune mechanisms are
presumably not so important, how-
ever, it is the factor that can be most
readily modified. Unfortunately, our
animal model was not suited to autol-
ogous pericardium implantation.
We strongly disagree with Mr
Love’s assertion that calcific degener-
ation never occurs in the pediatric
setting when glutaraldehyde-treated
autologous pericardium is used forry c Volume 144, Number 1 285
